Animal models: Usefulness for studies of fungal pathogenesis and drug efficacy in aspergillosis

Vincent T. Andriole, Peggy Miniter, David George, Dorsey Kordick, Thomas F Patterson

Research output: Contribution to journalArticle

Abstract

This review describes our experience during the past 8 years with an immunocompromised rabbit model of invasive aspergillosis. We have used the model to evaluate the efficacy of a variety of antifungal therapies, including amphotericin B-deoxycholate, a liposomal amphotericin B preparation, some of the newer azoles (i.e., fluconazole, saperconazole, and the experimental compound SCH 39304), and combination therapy with amphotericin B-deoxycholate plus fluconazole. The model provides a rigorous test of efficacy when animals receive a lethal challenge; permits studies of the kinetics of aspergillar antigenemia in response to therapy with each antifungal agent or regimen; allows comparison of the relation of antigenemia to the extent of disease in target organs; and is useful in correlating the timing of antifungal therapy with the success of treatment. These observations in our animal model may provide some insight into the treatment of invasive aspergillosis in humans.

Original languageEnglish (US)
Pages (from-to)S134-S138
JournalClinical Infectious Diseases
Volume14
DOIs
StatePublished - Mar 1 1992
Externally publishedYes

Fingerprint

Aspergillosis
Animal Models
Fluconazole
Pharmaceutical Preparations
Azoles
Antifungal Agents
Therapeutics
Rabbits
deoxycholate drug combination amphotericin B

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Animal models : Usefulness for studies of fungal pathogenesis and drug efficacy in aspergillosis. / Andriole, Vincent T.; Miniter, Peggy; George, David; Kordick, Dorsey; Patterson, Thomas F.

In: Clinical Infectious Diseases, Vol. 14, 01.03.1992, p. S134-S138.

Research output: Contribution to journalArticle

Andriole, Vincent T. ; Miniter, Peggy ; George, David ; Kordick, Dorsey ; Patterson, Thomas F. / Animal models : Usefulness for studies of fungal pathogenesis and drug efficacy in aspergillosis. In: Clinical Infectious Diseases. 1992 ; Vol. 14. pp. S134-S138.
@article{20f2c3107ad44247bad29b5f752e37b9,
title = "Animal models: Usefulness for studies of fungal pathogenesis and drug efficacy in aspergillosis",
abstract = "This review describes our experience during the past 8 years with an immunocompromised rabbit model of invasive aspergillosis. We have used the model to evaluate the efficacy of a variety of antifungal therapies, including amphotericin B-deoxycholate, a liposomal amphotericin B preparation, some of the newer azoles (i.e., fluconazole, saperconazole, and the experimental compound SCH 39304), and combination therapy with amphotericin B-deoxycholate plus fluconazole. The model provides a rigorous test of efficacy when animals receive a lethal challenge; permits studies of the kinetics of aspergillar antigenemia in response to therapy with each antifungal agent or regimen; allows comparison of the relation of antigenemia to the extent of disease in target organs; and is useful in correlating the timing of antifungal therapy with the success of treatment. These observations in our animal model may provide some insight into the treatment of invasive aspergillosis in humans.",
author = "Andriole, {Vincent T.} and Peggy Miniter and David George and Dorsey Kordick and Patterson, {Thomas F}",
year = "1992",
month = "3",
day = "1",
doi = "10.1093/clinids/14.Supplement_1.S134",
language = "English (US)",
volume = "14",
pages = "S134--S138",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Animal models

T2 - Usefulness for studies of fungal pathogenesis and drug efficacy in aspergillosis

AU - Andriole, Vincent T.

AU - Miniter, Peggy

AU - George, David

AU - Kordick, Dorsey

AU - Patterson, Thomas F

PY - 1992/3/1

Y1 - 1992/3/1

N2 - This review describes our experience during the past 8 years with an immunocompromised rabbit model of invasive aspergillosis. We have used the model to evaluate the efficacy of a variety of antifungal therapies, including amphotericin B-deoxycholate, a liposomal amphotericin B preparation, some of the newer azoles (i.e., fluconazole, saperconazole, and the experimental compound SCH 39304), and combination therapy with amphotericin B-deoxycholate plus fluconazole. The model provides a rigorous test of efficacy when animals receive a lethal challenge; permits studies of the kinetics of aspergillar antigenemia in response to therapy with each antifungal agent or regimen; allows comparison of the relation of antigenemia to the extent of disease in target organs; and is useful in correlating the timing of antifungal therapy with the success of treatment. These observations in our animal model may provide some insight into the treatment of invasive aspergillosis in humans.

AB - This review describes our experience during the past 8 years with an immunocompromised rabbit model of invasive aspergillosis. We have used the model to evaluate the efficacy of a variety of antifungal therapies, including amphotericin B-deoxycholate, a liposomal amphotericin B preparation, some of the newer azoles (i.e., fluconazole, saperconazole, and the experimental compound SCH 39304), and combination therapy with amphotericin B-deoxycholate plus fluconazole. The model provides a rigorous test of efficacy when animals receive a lethal challenge; permits studies of the kinetics of aspergillar antigenemia in response to therapy with each antifungal agent or regimen; allows comparison of the relation of antigenemia to the extent of disease in target organs; and is useful in correlating the timing of antifungal therapy with the success of treatment. These observations in our animal model may provide some insight into the treatment of invasive aspergillosis in humans.

UR - http://www.scopus.com/inward/record.url?scp=85047699320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047699320&partnerID=8YFLogxK

U2 - 10.1093/clinids/14.Supplement_1.S134

DO - 10.1093/clinids/14.Supplement_1.S134

M3 - Article

C2 - 1562686

VL - 14

SP - S134-S138

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

ER -